Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Blueprint Medicines develops precision therapies for genomically defined cancers and rare diseases.
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.
Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.
Tasso is a Medical innovation company changing the way diagnostics are delivered
Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.
Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
New Equilibrium Biosciences provides a platform that reveals opportunities for structure-based design by learning biophysics with AI.
Graphite Bio is a next-generation gene editing company that is driven to apply our breakthrough technology.
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product.
DTx Pharma is a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease.
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Kira Pharmaceuticals is a Biotechnology Research Company.
Locana develops RNA-targeting gene therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.
LianBio aims to develop and accelerate availability of paradigm-shifting medicines to patients in China.
RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics. The firm invests across 15 different industry categories.
Among tracked funding rounds, Blueprint Medicines received $1.3B in a Post Ipo Equity round. RA Capital Management's total known invested capital is $44.2B.
RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.
Recent RA Capital Management portfolio additions include Blueprint Medicines, Cerebral Therapeutics, Werewolf Therapeutics, Pardes Biosciences, Nodexus. These companies were founded in 2020 or later.